nach oben

Erschienen in:

01.07.2015 | Original Article

A feasibility dosimetric study on prostate cancer

Are we ready for a multicenter clinical trial on SBRT?

verfasst von: Carmelo Marino, Elena Villaggi, Giulia Maggi, Marco Esposito, Dr. Lidia Strigari, Elisa Bonanno, Giusi R. Borzì, Claudia Carbonini, Rita Consorti, David Fedele, Christian Fiandra, Isidora Ielo, Tiziana Malatesta, Maria Rosa Malisan, Anna Martinotti, Renzo Moretti, Barbara Nardiello, Caterina Oliviero, Stefania Clemente, Pietro Mancosu

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The Italian Association of Medical Physics (AIFM) started a working group dedicated to stereotactic body radiotherapy (SBRT) treatment. In this work, we performed a multicenter planning study on patients who were candidates for SBRT in the treatment of prostate cancer with the aim of evaluating the dosimetric consistency among the different hospitals.

Methods and materials

Fourteen centers were provided the contours of 5 patients. Plans were performed following the dose prescription and constraints for organs at risk (OARs) of a reference paper. The dose prescription was 35 Gy in five fractions for the planning target volume (PTV). Different techniques were used (3D-CRT, fixed-Field IMRT, VMAT, CyberKnife). Plans were compared in terms of dose–volume histogram (DVH) parameters. Furthermore, the median DVH was calculated and one patient was re-planned.

Results

A total of 70 plans were compared. The maximum dose to the body was 107.9 ± 4.5 % (range 101.5–116.3 %). Dose at 98 % (D_98 %) and mean dose to the clinical target volume (CTV) were 102.0 ± 0.9 % (global range 101.1–102.9 %) and 105.1 ± 0.6 % (range 98.6–124.6 %). Similar trends were found for D_95 % and mean dose to the PTV. Important differences were found in terms of the homogeneity index. Doses to OARs were heterogeneous. The subgroups with the same treatment planning system showed differences comparable to the differences of the whole group. In the re-optimized plans, DVH differences among institutes were reduced and OAR sparing improved.

Conclusion

Important dosimetric differences with possible clinical implications, in particular related to OARs, were found. Replanning allowed a reduction in the OAR dose and decreased standard deviations. Multicenter clinical trials on SBRT should require a preplanning study to standardize the optimization procedure.

Miles EF, Lee WR (2008) Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol 18:41–47PubMedCrossRef

Arcangeli S, Scorsetti M, Alongi F (2012) Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Critic Rev Oncol Hematol 84:101–108CrossRef

Fowler JF (2005) The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44:265–276PubMedCrossRef

Fowler JF et al (2003) What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 56:1093–1104PubMedCrossRef

Pollack A, Walker G, Horwitz EM et al (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31:3860–3868PubMedCentralPubMedCrossRef

Lee WR (2013) Prostate cancer and the hypofractionation hypothesis. J Clin Oncol 31:3849–3851PubMedCrossRef

Arcangeli S, Strigari L, Gomellini S et al (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84:1172–1178PubMedCrossRef

King CR, Freeman D, Kaplan I et al (2013) Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. doi:10.1016/j.radonc.2013.08.030

Freeman DE, King CR (2011) Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 6:3. doi:10.1186/1748-717X-6-3PubMedCentralPubMedCrossRef

10.

Guckenberger M, Andratschke N, Alheit H et al (2014) Definition of stereotactic body radiotherapy. Strahlenther Onkol 190:26–33PubMedCentralPubMedCrossRef

11.

Vogelius IR, Bentzen SM (2013) Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85:89–94PubMedCentralPubMedCrossRef

12.

Kirkbride P, Cooper T (2011) Stereotactic body radiotherapy. Guidelines for commissioners, providers and clinicians: a national report. Clin Oncol 23:163–164CrossRef

13.

Zaorsky NG, Ohri N, Showalter TN et al (2013) Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev 39:728–736PubMedCrossRef

14.

Loblaw A, Cheung P, D’Alimonte L et al (2013) Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol 107:153–158PubMedCrossRef

15.

Alongi F, Fogliata A, Navarria P et al (2012) Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (Rapid arc) for prostate cancer. Report of feasibility and acute toxicity. Strahlenther Onkol 188:990–996PubMedCrossRef

16.

Kataria T et al (2012) Homogeneity Index: an objective tool for assessment of conformal radiation treatments. J Med Phys. 37:207–213. doi:10.4103/0971-6203.103606PubMedCentralPubMedCrossRef

17.

Guckenberger M et al (2014) Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT. Strahlenther Onkol 190:48–53PubMedCrossRef

18.

Sanpaolo P et al (2014) Biologically effective dose and definitive radiation treatment for localized prostate cancer: treatment gaps do affect the risk of biochemical failure. Strahlenther Onkol 190:732–738PubMedCrossRef

19.

Clemente S et al (2015) Role of the technical aspects of hypofractionated radiation therapy treatment of prostate cancer: a review. Int J Radiat Oncol Biol Phys 91:182–195CrossRef

20.

Murray LJ et al (2014) Developing a class solution for Prostate Stereotactic Ablative Body Radiotherapy (SABR) using Volumetric Modulated Arc Therapy (VMAT). Radiother Oncol 110:298–302PubMedCentralPubMedCrossRef

21.

Tree A, Ostler P, van As N (2014) New horizons and hurdles for UK radiotherapy: can prostate stereotactic body radiotherapy show the way? Clin Oncol 26:1–3CrossRef

22.

Bekelman JE et al (2012) Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys 83:782–790PubMedCentralPubMedCrossRef

23.

MacDougall ND, Dean C, Muirhead R (2014) Stereotactic body radiotherapy in prostate cancer: is rapid arc a better solution than cyberknife? Clin Oncol 26:4–9CrossRef

24.

Dorr W, Herrmann T, Baumann M (2014) Application of organ tolerance dose-constraints in clinical studies in radiation oncology. Strahlenther Onkol 190:621–627PubMedCrossRef

25.

Eriguchi T et al (2013) Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma-benchmark for a prospective multi-institutional study. Radiat Oncol 8:113PubMedCentralPubMedCrossRef

26.

Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 37:4078–4101PubMedCrossRef

27.

Hazard LJ, Wang B, Skidmore TB et al (2009) Conformity of LINAC-based stereotactic radiosurgery using dynamic conformal arcs and micro-multileaf collimator. Int J Radiat Oncol Biol Phys 73:562–570PubMedCrossRef

28.

Ohtakara K, Hayashi S, Hoshi H (2012) The relation between various conformity indices and the influence of the target coverage difference in prescription isodose surface on these values in intracranial stereotactic radiosurgery. Br J Rad 85:e223–e228CrossRef

29.

Hong LX et al (2011) Experience of micromultileaf collimator linear accelerator based single fraction stereotactic radiosurgery: tumor dose inhomogeneity, conformity, and dose fall off. Med Phys 38:1239–1247PubMedCrossRef

30.

Schick U et al (2011) Stereotactic body radiotherapy: overview of the 2010 Royal College of Radiologists’ annual scientific meeting. Clin Oncol 23:165–167CrossRef

31.

Lo SS, Sahgal A, Chang EL et al (2013) Serious complications associated with stereotactic ablative radiotherapy and strategies to mitigate the risk. Clin Oncol 25:378–387CrossRef

32.

Wagner TH (2003) A simple and reliable index for scoring rival stereotactic radiosurgery plans. Int J Radiat Oncol Biol Phys 57:1141–1149PubMedCrossRef

33.

Knöös, T, Wieslander E, Cozzi L et al (2006) Comparison of dose calculation algorithms for treatment planning in external photon beam therapy for clinical situations. Phys Med Biol 51:5785–5807PubMedCrossRef

34.

Aspradakis MM, Morrison RH, Richmond ND, Steele A (2003) Experimental verification of convolution/superposition photon dose calculations for radiotherapy treatment planning. Phys Med Biol 48:2873–2893PubMedCrossRef

Titel: A feasibility dosimetric study on prostate cancer
Are we ready for a multicenter clinical trial on SBRT?
verfasst von: Carmelo Marino
Elena Villaggi
Giulia Maggi
Marco Esposito
Dr. Lidia Strigari
Elisa Bonanno
Giusi R. Borzì
Claudia Carbonini
Rita Consorti
David Fedele
Christian Fiandra
Isidora Ielo
Tiziana Malatesta
Maria Rosa Malisan
Anna Martinotti
Renzo Moretti
Barbara Nardiello
Caterina Oliviero
Stefania Clemente
Pietro Mancosu
Publikationsdatum: 01.07.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 7/2015
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-015-0822-6

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

A feasibility dosimetric study on prostate cancer

Are we ready for a multicenter clinical trial on SBRT?